<DOC>
	<DOCNO>NCT02872142</DOCNO>
	<brief_summary>This pilot , phase IIa , prospective , open-label , single-arm study evaluate disease progression , force vital capacity , safety tolerability plasma exchange ( PE ) use Albutein® 5 % subject amyotrophic lateral sclerosis ( ALS ) .</brief_summary>
	<brief_title>Efficacy Safety Plasma Exchange With Albutein® 5 % Patients With Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>This phase IIa , prospective , open-label , single-arm pilot study evaluate efficacy safety PE Albutein® 5 % subject ALS . The planned enrollment 10 subject definite , possible , probable diagnosis ALS , accord revise El Escorial criterion . Enrolled subject treat PE use Albutein 5 % replacement solution Intensive Treatment Phase ( 2 PEs per week 3 week ) follow Maintenance Treatment Phase ( weekly PE 21 week ) total treatment duration 6 month . A 6-month follow begin last PE .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Signed informed consent Subjects 18 year age less 70 year old Subjects possible , probablelab support , probable , definite diagnosis ALS , accord revise El Escorial criterion Subjects experience first ALS symptom within 18 month prior recruitment/consent Forced Vital Capacity &gt; 70 % Subjects must medically suitable study participation willing comply plan aspect protocol , include blood sampling , time inclusion study . Subjects preexist clinically significant lung disease attributable ALS Subjects diagnose neurodegenerative disease disease associate motor neuron dysfunction Participation another investigational product study within one month prior screen Females pregnant , breastfeeding , , childbearing potential , unwilling practice highly effective method contraception ( oral , injectable implanted hormonal method contraception , placement intrauterine device intrauterine system , condom occlusive cap spermicidal foam/ gel/ film/ cream/ suppository , male sterilization , true abstinence ) throughout study Difficult problematic peripheral vein access inability implant central catheter would make continuous PE feasible per visit protocol Contraindication undergo PE subject abnormal coagulation parameter discretion Outpatient Apheresis Unit team , include limited : 1 . Thrombocytopenia ( platelet &lt; 100,000/μL ) 2 . Fibrinogen &lt; 1.5 g/L 3. International Normalized Ratio &gt; 1.5 4 . Betablocker treatment bradycardia &lt; 50 beats/min 5 . Treatment angiotensinconverting enzyme inhibitor may increase risk allergic reaction , unless preventive change hypotensive treatment occur prior enrollment History anaphylaxis severe systemic response plasmaderived albumin preparation , component Albutein® 5 % , blood product ( ) Subjects unable interrupt treatment acetylsalicylic acid , oral antiplatelet , anticoagulant Renal dysfunction elevate creatinine concentration &gt; 2 mg/dL Presence heart disease contraindicate PE treatment , include ischemic cardiopathy congestive heart failure Presence prior behavioral disorder require pharmacological intervention le 3 month stable treatment Mentally challenge subject give independent inform consent Any condition would complicate compliance study protocol ( i.e. , illness expectation less one year survival , abuse drug alcohol , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>